JP2021515541A5 - - Google Patents

Info

Publication number
JP2021515541A5
JP2021515541A5 JP2020542228A JP2020542228A JP2021515541A5 JP 2021515541 A5 JP2021515541 A5 JP 2021515541A5 JP 2020542228 A JP2020542228 A JP 2020542228A JP 2020542228 A JP2020542228 A JP 2020542228A JP 2021515541 A5 JP2021515541 A5 JP 2021515541A5
Authority
JP
Japan
Prior art keywords
seq
antibody
amino acid
acid sequence
antigen
Prior art date
Application number
JP2020542228A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021515541A (ja
JPWO2019170898A5 (https=
Filing date
Publication date
Priority claimed from GBGB1803746.5A external-priority patent/GB201803746D0/en
Application filed filed Critical
Publication of JP2021515541A publication Critical patent/JP2021515541A/ja
Publication of JP2021515541A5 publication Critical patent/JP2021515541A5/ja
Publication of JPWO2019170898A5 publication Critical patent/JPWO2019170898A5/ja
Pending legal-status Critical Current

Links

JP2020542228A 2018-03-08 2019-03-08 Ｐｄ１結合剤 Pending JP2021515541A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB1803746.5 2018-03-08
GBGB1803746.5A GB201803746D0 (en) 2018-03-08 2018-03-08 PD1 binding agents
GB1813405.6 2018-08-16
GBGB1813405.6A GB201813405D0 (en) 2018-03-08 2018-08-16 PD1 binding agents
PCT/EP2019/055927 WO2019170898A1 (en) 2018-03-08 2019-03-08 Pd1 binding agents

Publications (3)

Publication Number Publication Date
JP2021515541A JP2021515541A (ja) 2021-06-24
JP2021515541A5 true JP2021515541A5 (https=) 2022-03-15
JPWO2019170898A5 JPWO2019170898A5 (https=) 2022-03-15

Family

ID=61972796

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020542228A Pending JP2021515541A (ja) 2018-03-08 2019-03-08 Ｐｄ１結合剤

Country Status (10)

Country Link
US (2) US10858435B2 (https=)
EP (1) EP3762419A1 (https=)
JP (1) JP2021515541A (https=)
CN (1) CN111819199A (https=)
AU (1) AU2019229676A1 (https=)
CA (1) CA3092174A1 (https=)
GB (2) GB201803746D0 (https=)
IL (1) IL277135A (https=)
SG (1) SG11202008246VA (https=)
WO (1) WO2019170898A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA034666B1 (ru) 2013-09-13 2020-03-04 Бейджин Свитзерланд Гмбх Антитело против pd-1 и его применение для лечения рака или вирусной инфекции и фрагмент антитела
TWI726608B (zh) 2014-07-03 2021-05-01 英屬開曼群島商百濟神州有限公司 抗pd-l1抗體及其作為治療及診斷之用途
US10864203B2 (en) 2016-07-05 2020-12-15 Beigene, Ltd. Combination of a PD-1 antagonist and a RAF inhibitor for treating cancer
PT3500299T (pt) 2016-08-19 2024-02-21 Beigene Switzerland Gmbh Combinação de zanubrutinib com um anticorpo anti-cd20 ou anti-pd-1 para utilização no tratamento do cancro
EP3573989A4 (en) 2017-01-25 2020-11-18 Beigene, Ltd. CRYSTALLINE FORMS OF (S) -7- (1- (BUT-2-YNOYL) PIPERIDIN-4-YL) -2- (4-PHENOXYPHENYL) -4, 5, 6, 7-TETRAHY DROPYRAZOLO [1, 5-A ] PYRIMIDINE-3-CARBOXAMIDE, PREPARATION AND ASSOCIATED USES
TW202515616A (zh) 2017-06-26 2025-04-16 英屬開曼群島商百濟神州有限公司 抗pd-1抗體或其抗原結合片段在製備治療用於患有肝細胞癌(hcc)之藥物的用途
CN111801334B (zh) 2017-11-29 2023-06-09 百济神州瑞士有限责任公司 使用包含btk抑制剂的组合治疗惰性或侵袭性b-细胞淋巴瘤
GB201803745D0 (en) 2018-03-08 2018-04-25 Ultrahuman Eight Ltd PD1 binding agents
GB201914747D0 (en) 2019-10-11 2019-11-27 Ultrahuman Eight Ltd PD1 and vegfr2 dual-binding agents
AU2020366257B2 (en) * 2019-10-15 2025-01-23 Diverse Biotech, Inc. Conjugate molecules
BR112022023989A2 (pt) 2020-05-26 2023-02-07 Boehringer Ingelheim Int Anticorpos anti-pd-1

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2494107C2 (ru) * 2005-05-09 2013-09-27 Оно Фармасьютикал Ко., Лтд. Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами
EA034666B1 (ru) 2013-09-13 2020-03-04 Бейджин Свитзерланд Гмбх Антитело против pd-1 и его применение для лечения рака или вирусной инфекции и фрагмент антитела
MY184154A (en) * 2013-12-12 2021-03-23 Shanghai hengrui pharmaceutical co ltd Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof
NZ739090A (en) * 2015-10-02 2025-06-27 Hoffmann La Roche Bispecific antibodies specific for pd1 and tim3
GB201803745D0 (en) 2018-03-08 2018-04-25 Ultrahuman Eight Ltd PD1 binding agents

Similar Documents

Publication Publication Date Title
JP2021515541A5 (https=)
JP2021519100A5 (https=)
JP2021515542A5 (https=)
JPWO2019185717A5 (https=)
JPWO2019155067A5 (https=)
JP2021516537A5 (https=)
JP2019201643A5 (https=)
FI4041763T3 (fi) Pd1:tä ja vegfr2:ta kaksoissitovia aineita
JP2017149720A5 (https=)
RU2017145150A (ru) Антитело против pdl-1, его фармацевтическая композиция и применение
HRP20200583T1 (hr) Protutijela koja neutraliziraju gp120 i njihova upotreba
JP2018522541A5 (https=)
JP2020514277A5 (https=)
JP2018506961A5 (https=)
RU2019121086A (ru) Иммунотерапия с применением антител, связывающих лиганд 1 белка программируемой смерти клеток (PD-L1)
JP2021534797A5 (https=)
JP2020513759A5 (https=)
JP2021515544A5 (https=)
JP2021514654A5 (https=)
JPWO2019170898A5 (https=)
AU2020412201A1 (en) TGF-beta-RII binding proteins
JPWO2019170885A5 (https=)
JPWO2022221409A5 (https=)
JPWO2021069670A5 (https=)
JPWO2019175186A5 (https=)